Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) PT at $26.00

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have received an average rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $26.00.

A number of research analysts have recently commented on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $17.14 on Thursday. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09. The business has a 50 day moving average price of $16.45 and a 200 day moving average price of $16.29. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -11.20 and a beta of 1.54.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the transaction, the general counsel now owns 105,386 shares in the company, valued at $1,705,145.48. This represents a 5.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares of the company’s stock, valued at approximately $5,273,100.81. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 353,310 shares of company stock valued at $5,917,155. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $31,000. Woodline Partners LP boosted its holdings in Centessa Pharmaceuticals by 5.7% in the 4th quarter. Woodline Partners LP now owns 545,645 shares of the company’s stock worth $9,140,000 after acquiring an additional 29,266 shares during the period. Squarepoint Ops LLC boosted its holdings in Centessa Pharmaceuticals by 33.2% in the 4th quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock worth $449,000 after acquiring an additional 6,685 shares during the period. Stempoint Capital LP boosted its holdings in Centessa Pharmaceuticals by 667.3% in the 4th quarter. Stempoint Capital LP now owns 641,964 shares of the company’s stock worth $10,753,000 after acquiring an additional 558,302 shares during the period. Finally, Shay Capital LLC purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $239,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.